QuidelOrtho

QDEL · NASDAQ

$14.21+$1.45 (+11.36%)TodayMarket closed · Oct 20, 7:48 PM ET

Prev close $12.76

QDEL analyst rating

HoldConsensus of 4 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform1
Sell0

12-month price target · 5 analysts

Average $16.32 (+14.8% upside)

Low: $12.12
Now: $14.21
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

QDEL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Jul 8, 2026	Maintains	Neutral	$13.00 → $18.00	55%
JP Morgan	Jul 1, 2026	Maintains	Underweight	$11.00 → $12.00	71%
Jefferies	May 7, 2026	Downgrade	Buy → Hold	$35.00 → $12.50	64%
Citigroup	May 6, 2026	Maintains	Neutral	$30.00 → $13.00	55%
UBS	Apr 10, 2026	Maintains	Neutral	$30.00 → $17.00	86%
Citigroup	Feb 12, 2026	Maintains	Neutral	$23.00 → $30.00	55%
UBS	Jan 21, 2026	Maintains	Neutral	$31.00 → $35.00	86%
JP Morgan	Nov 7, 2025	Maintains	Underweight	$26.00 → $22.00	71%
UBS	Nov 6, 2025	Maintains	Neutral	$26.00 → $31.00	86%

The case for and against

Updated Jan 22, 2025

Bull case

QuidelOrtho Corp has demonstrated strong free cash flow generation, primarily driven by its leadership in point-of-care COVID and flu testing, which positions the company well for future prospects. The merger with Ortho has expanded its product portfolio, allowing QuidelOrtho to effectively compete with larger enterprises in the diagnostics market. Additionally, the transition of legacy operations to the Ortho IT platform is expected to yield long-term cost savings and operational efficiencies, supporting continued margin expansion.

Bear case

QuidelOrtho Corp faces significant challenges that contribute to a negative outlook, particularly due to uncertainty surrounding the launch of its Savanna product and potential loss of market share in the point-of-care and laboratory sectors. The company also risks margin contraction and may struggle with debt repayment, factors that could justify a revised sales multiple at 1.3x, the historical low for comparable non-molecular diagnostics companies. Additionally, ongoing issues related to endemic COVID impacts, ERP consolidation, and lack of clear guidance further compound the risk of achieving long-term financial targets, highlighting potential integration difficulties.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.